首页> 美国卫生研究院文献>Springer Open Choice >HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
【2h】

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients

机译:HER2基因和蛋白质同时评估对HER2肿瘤内异质性的预测用于HER2阴性浸润性乳腺癌患者的预后

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

HER2 gene-protein assay (GPA) is a new method for the simultaneous evaluation of HER2 immunohistochemistry (IHC) and HER2 dual in situ hybridization (DISH) on single tissue sections of breast cancer. We investigated the presence of HER2 gene and protein discrepancy and HER2-heterogeneity using HER2-GPA. HER2 status was analyzed for the correlation between the presence of HER2-heterogeneity and patient prognosis. Consecutive 280 invasive breast cancer were examined. Statuses of HER2 protein and gene were evaluated in whole tumor sections of HER2 GPA slides. HER2 protein and gene combination patterns were classified to six phenotypic and genotypic types for each case, as well as at individual cell levels: (A) IHC and DISH positive; (B) IHC positive and DISH negative; (C) IHC equivocal and DISH positive; (D) IHC equivocal and DISH negative; (E) IHC negative and DISH positive; and (F) IHC and DISH negative. The presence of HER2-heterogeneity was determined by the existence of at least two of six types within one tumor. HER2-IHC positive patients had significantly worse survival than IHC negative patients and HER2-DISH positive patients had significantly worse survival than DISH negative patients. HER2 IHC negative and DISH positive patients had significantly worse recurrence-free survival than IHC and DISH negative patients. In the HER2 IHC and DISH negative group, the HER2 heterogeneous group had significantly worse survival than the nonheterogeneous group. Notably, among triple negative breast cancer (TNBC), the HER2 heterogeneous group had significantly worse survival than the nonheterogeneous group. Our study suggests that the presence of HER2-heterogeneity might be a prognostic factor in HER2 negative breast cancer patients, especially in TNBC.Electronic supplementary materialThe online version of this article (doi:10.1007/s10549-016-3856-2) contains supplementary material, which is available to authorized users.
机译:HER2基因蛋白测定法(GPA)是一种同时评估乳腺癌单个组织切片上的HER2免疫组织化学(IHC)和HER2双原位杂交(DISH)的新方法。我们使用HER2-GPA调查了HER2基因的存在和蛋白质差异以及HER2-异质性。分析HER2状态以了解HER2异质性的存在与患者预后之间的相关性。连续检查了280例浸润性乳腺癌。在HER2 GPA载玻片的整个肿瘤切片中评估了HER2蛋白和基因的状态。每种情况下,以及在单个细胞水平上,HER2蛋白和基因组合模式分为六种表型和基因型类型:(A)IHC和DISH阳性; (B)IHC阳性,DISH阴性; (C)IHC含糊不清,DISH阳性; (D)IHC模棱两可,DISH阴性; (E)IHC阴性,DISH阳性; (F)IHC和DISH阴性。 HER2异质性的存在是由一种肿瘤内六种类型中至少两种的存在来确定的。 HER2-IHC阳性患者的生存率显着低于IHC阴性患者,HER2-DISH阳性患者的生存率显着低于DISH阴性患者。 HER2 IHC阴性和DISH阳性患者的无复发生存率明显高于IHC和DISH阴性患者。在HER2 IHC和DISH阴性组中,HER2异质组的生存期显着低于非异质组。值得注意的是,在三阴性乳腺癌(TNBC)中,HER2异种组的存活率显着低于非异种组。我们的研究表明HER2异质性的存在可能是HER2阴性乳腺癌患者的预后因素,尤其是在TNBC中。电子补充材料本文的在线版本(doi:10.1007 / s10549-016-3856-2)包含补充材料,可供授权用户使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号